Lōkahi Therapeutics signs first external client for asset search platform

Lōkahi Therapeutics Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), announced that Innovate GBM, a nonprofit organization focused on glioblastoma treatments, has engaged two project teams through Lōkahi's ai² PIPELINE platform on a fee-for-service basis to identify brain tumor therapeutic assets available for licensing and development.

According to the press release, Innovate GBM is the first external organization to access the ai² PIPELINE, which Lōkahi previously operated solely as an internal asset discovery process. The platform operates through a network of 14 university collaborations. Innovate GBM will independently determine whether to pursue any asset identified through the engagement.

"Innovate GBM's engagement is the next step forward for the ai² PIPELINE as it moves the platform from a company-led initiative to a model that outside organizations can put to work," said Erik Emerson, Chief Executive Officer of Glucotrack.

Kush Thukral, Co-Executive Director of Innovate GBM, said the platform offers "a disciplined, capital-efficient way to search systematically for overlooked brain tumor assets" in glioblastoma, which he described as "one of the hardest problems in oncology."

Lōkahi stated that the sponsor-led model could be extended to pharmaceutical companies, biotechnology companies, and investment organizations. The company did not disclose financial terms of the Innovate GBM engagement.

You May Also Be Interested In

• CareDx data links AlloSure Kidney test to graft outcome risk
• HSBC Starts Ameren Corp. (AEE) at Buy
• HSBC Starts CMS Energy (CMS) at Hold